Amin Javidanbardan

1 Introduction Messenger Ribonucleic acid (mRNA) is a relatively new class of therapeutic, showing great promise due to its clinical versatility and rapid development timelines. mRNA-based therapeutics are cost-effective, simple to manufacture, and can target a broad range of diseases, including pathogenic infections as well as numerous metabolic, genetic, and cardiovascular disorders (Qin et al. 2022; Alberer et al. 2017; Feldman et al. 2019).

1 Introduction Monoclonal antibodies (mAbs) and their derivatives are a critical class of biopharmaceuticals, but their purification presents substantial challenges due to structural heterogeneity and process-related impurities.

Highlights Successful development of nucleic acid therapeutics requires effective manufacturing strategies tailored to the production and purification of RNA and DNA. Membrane processes can be used for initial clarification, removal of smaller host cell proteins and transcription factors, concentration and buffer exchange, and sterile filtration. Transmission of DNA and RNA in ultrafiltration is governed by both the effective size and elongational flexibility of the nucleic acids.